The Liver as a Biomarker Organ in Heart Failure: Molecular Mechanisms, Hepatic Scores and Systemic Risk Stratification
Open Access
- 23 August 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7545
Abstract
Heart failure (HF) is a systemic syndrome in which prognosis depends on cardiac dysfunction, congestion, cardiorenal and cardiohepatic interactions, inflammation, and metabolic dysregulation. The liver is exposed to elevated systemic venous pressure and reduced forward flow, and contributes to albumin and coagulation factor synthesis, bile acid metabolism, iron homeostasis, and the acute-phase response. Cardiohepatic injury involves hemodynamic stress, sinusoidal endothelial dysfunction, oxidative stress, inflammatory signaling, fibrogenesis, and altered metabolic regulation. Congestive hepatopathy is associated with right-sided HF, tricuspid regurgitation (TR), pulmonary hypertension, and elevated central venous pressure, whereas hypoxic hepatitis develops during low-output states, shock, or acute circulatory deterioration. These mechanisms may coexist, producing congestive/cholestatic, hypoperfusive/ischemic and mixed/systemic reserve profiles. Composite liver-related scores, including Model for End-Stage Liver Disease (MELD), MELD excluding International Normalized Ratio (MELD-XI), MELD with sodium (MELD-Na), MELD-Albumin and albumin–bilirubin (ALBI) score, may reflect congestion, hepatorenal dysfunction, nutritional status and reduced systemic reserve. This review summarizes hemodynamic and molecular mechanisms of cardiohepatic injury, liver-related biomarkers and composite scores, with emphases on advanced HF, left ventricular assist device (LVAD) therapy and heart transplantation. Liver-related abnormalities remain underrecognized in HF. Their serial interpretation may support risk stratification, but composite scores should complement rather than replace comprehensive clinical assessment.Keywords
This publication has 69 references indexed in Scilit:
- The evolving concept from Cardiovascular-kidney-metabolic syndrome to metabolic associated liver-cardiovascular-kidney syndrome: insights from endocrinologyReviews in Endocrine and Metabolic Disorders, 2026
- Fibroblast growth factor 21 in heart failureHeart Failure Reviews, 2022
- Prognostic Value of the Liver Fibrosis Marker Fibrosis-5 Index in Patients with Acute Heart FailureESC Heart Failure, 2022
- The Clinical Significance of Interleukin-6 in Heart Failure: Results from the BIOSTAT-CHF StudyEuropean Journal of Heart Failure, 2019
- Model of End-Stage Liver Disease-eXcluding International Normalized Ratio (MELD-XI) Scoring System to Predict Outcomes in Patients Who Undergo Left Ventricular Assist Device ImplantationThe Annals of Thoracic Surgery, 2018
- Congestive hepatopathy: Differentiating congestion from fibrosisClinical Liver Disease, 2017
- Organ Dysfunction, Injury and Failure in Acute Heart Failure: From Pathophysiology to Diagnosis and Management. A Review on Behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)European Journal of Heart Failure, 2017
- Impaired Hepato-Renal Function Defined by the MELD XI Score as Prognosticator in Acute Heart FailureEuropean Journal of Heart Failure, 2016
- Abnormal Liver Function Tests in Acute Heart Failure: Relationship with Clinical Characteristics and Outcome in the PROTECT StudyEuropean Journal of Heart Failure, 2016
- MELD-XI: A rational approach to “sickest first” liver transplantation in cirrhotic patients requiring anticoagulant therapyLiver Transplantation, 2006